word,tfidf
analysis,0.2272777532603025
month,0.20086465526418806
week,0.18747367824657551
95,0.17146312398756125
analyses,0.16544687402308542
test,0.15072103637262166
arms,0.14739812412965794
estimated,0.13837374918294418
arm,0.1363666519561815
intent,0.1356580492516015
endpoints,0.13123157477260286
primary,0.1267970623452214
response,0.12440466494248138
bayesian,0.12234055858211564
probability,0.11961987013700132
estimator,0.11678346793956342
interquartile,0.11678346793956342
interim,0.11430874932504084
randomized,0.1124842069479453
endpoint,0.1124842069479453
median,0.112145512033606
treat,0.11130062434280293
rate,0.11005028052604121
competing,0.10780012425190469
compared,0.1071278161409003
efficacy,0.10177142533385529
characteristics,0.1004806909150811
confidence,0.09881678056424596
described,0.09625999943161334
range,0.09175541893658673
design,0.09024374946713751
exact,0.08983343687658725
ci,0.08914671807962384
statistical,0.08835707008708352
data,0.08612630649864095
12,0.08612630649864095
percentages,0.08534176503275788
incidence,0.08302405750919772
safety,0.0813415116931609
set,0.08121937452042376
sided,0.08085009318892852
cohort,0.07816202353857388
kaplan,0.07751888528662942
gray,0.07635842134509915
group,0.07416431948494083
risks,0.07364294102229796
model,0.07177192208220079
24,0.07177192208220079
summary,0.07136532583956745
included,0.06963308049158519
effect,0.06963308049158519
posterior,0.06937952467946078
binomial,0.06796697699006424
events,0.06698712727672074
computed,0.06617874960923417
sample,0.06617874960923417
beta,0.06317062462699626
secondary,0.06220233247124069
adverse,0.06220233247124069
survival,0.06220233247124069
meier,0.06201510822930354
means,0.06201510822930354
models,0.06016249964475834
stage,0.058920298877495156
summarized,0.05839173396978171
informative,0.057771930441554604
tests,0.057771930441554604
intervals,0.057771930441554604
event,0.05741753766576063
difference,0.05715437466252042
16,0.05624210347397265
criteria,0.05624210347397265
20,0.055025140263020605
disease,0.055025140263020605
quantitative,0.054263219700640596
log,0.054263219700640596
hazard,0.053900062125952344
categorical,0.053900062125952344
inclusion,0.05263274286028058
cumulative,0.05113812469804458
counts,0.050885712666927645
presented,0.050885712666927645
linear,0.04940839028212298
significance,0.04940839028212298
cox,0.04940839028212298
following,0.04784794805480053
measures,0.04784794805480053
observed,0.04784794805480053
inference,0.04757688389304497
combination,0.04757688389304497
planned,0.04757688389304497
distribution,0.04757688389304497
rank,0.04757688389304497
toxicity,0.04545555065206051
phase,0.04545555065206051
considered,0.04545555065206051
ii,0.04545555065206051
05,0.045121874733568754
sas,0.044916718438293625
disposition,0.044916718438293625
random,0.04417853504354176
strategy,0.04417853504354176
methods,0.04417853504354176
end,0.043063153249320474
comparison,0.04285112645636012
size,0.04285112645636012
experimental,0.04285112645636012
type,0.04285112645636012
use,0.04285112645636012
given,0.04285112645636012
error,0.042635386907646185
censored,0.042635386907646185
analysed,0.04211374975133084
continuous,0.040780186194038545
intolerance,0.040780186194038545
rules,0.040780186194038545
follow,0.04067075584658045
distributions,0.04042504659446426
logrank,0.04042504659446426
general,0.03910562476909291
criterion,0.03910562476909291
inclusions,0.03875944264331471
versus,0.03827835844384042
graft,0.03827835844384042
pt,0.03738183734453533
observations,0.036097499786854996
stopping,0.036097499786854996
iqr,0.0359333747506349
priors,0.0359333747506349
greater,0.035885961041100395
stop,0.03488349837898324
org,0.03488349837898324
estimates,0.03488349837898324
baseline,0.034816540245792595
stopped,0.03398348849503212
compare,0.03398348849503212
similarly,0.03398348849503212
relapse,0.03349356363836037
host,0.03349356363836037
30,0.03349356363836037
assessed,0.03349356363836037
free,0.032138344842270086
frequency,0.032138344842270086
received,0.032138344842270086
51,0.03144170290680553
power,0.03144170290680553
terminal,0.03144170290680553
table,0.03008124982237917
post,0.028708768832880316
overall,0.028708768832880316
level,0.028708768832880316
sequential,0.027186790796025696
monotherapy,0.027186790796025696
changes,0.027186790796025696
futility,0.027131609850320298
promising,0.027131609850320298
project,0.027131609850320298
enrolled,0.02707312484014125
unacceptable,0.02707312484014125
setting,0.02707312484014125
logistic,0.026950031062976172
principle,0.026950031062976172
fisher,0.026950031062976172
proportional,0.026950031062976172
packages,0.026950031062976172
percentage,0.026781954035225077
completed,0.026781954035225077
factors,0.026781954035225077
population,0.026781954035225077
considering,0.026781954035225077
monitoring,0.026781954035225077
55,0.02631637143014029
remission,0.02631637143014029
death,0.02631637143014029
interval,0.02631637143014029
total,0.02631637143014029
mean,0.024103758631702568
100,0.024103758631702568
required,0.024103758631702568
calculated,0.024103758631702568
www,0.024064999857903335
maximum,0.024064999857903335
discontinuation,0.024064999857903335
10,0.023923974027400267
best,0.023923974027400267
transplantation,0.023923974027400267
includes,0.023923974027400267
main,0.023923974027400267
complete,0.023923974027400267
prognostic,0.023788441946522486
consider,0.023788441946522486
software,0.023788441946522486
unless,0.023788441946522486
borr,0.023788441946522486
binary,0.023788441946522486
adjustment,0.023255665585988825
observation,0.023255665585988825
alpha,0.023255665585988825
conducted,0.023255665585988825
compute,0.023255665585988825
nc,0.022458359219146812
nonparametric,0.022458359219146812
cary,0.022458359219146812
estimations,0.022458359219146812
hazards,0.022458359219146812
randomization,0.021531576624660237
potential,0.021531576624660237
value,0.021531576624660237
treated,0.021531576624660237
cell,0.021531576624660237
transplant,0.021531576624660237
quality,0.021531576624660237
spartalizumab,0.02142556322818006
point,0.02142556322818006
25,0.02142556322818006
normal,0.02142556322818006
2014,0.02142556322818006
36,0.02142556322818006
responses,0.02142556322818006
measured,0.02105687487566542
reasons,0.02105687487566542
http,0.02105687487566542
expected,0.02105687487566542
enrolment,0.02105687487566542
exploratory,0.020390093097019273
threshold,0.020390093097019273
administered,0.020390093097019273
inferiority,0.020390093097019273
adjusted,0.019379721321657356
null,0.019379721321657356
actually,0.019379721321657356
framework,0.019379721321657356
evaluating,0.019379721321657356
sectional,0.019379721321657356
permanently,0.019379721321657356
resources,0.019379721321657356
specifically,0.019379721321657356
called,0.019379721321657356
treatments,0.01913917922192021
sensitivity,0.01913917922192021
acute,0.01913917922192021
progression,0.01913917922192021
60,0.01913917922192021
information,0.01913917922192021
groups,0.01913917922192021
points,0.01874736782465755
score,0.01874736782465755
historical,0.01874736782465755
approach,0.01874736782465755
occurrence,0.01874736782465755
evaluated,0.01874736782465755
evaluation,0.01874736782465755
ratio,0.01874736782465755
regression,0.018048749893427498
section,0.018048749893427498
recorded,0.018048749893427498
hypothesis,0.018048749893427498
property,0.01796668737531745
propensity,0.01796668737531745
assuming,0.01796668737531745
operating,0.01796668737531745
credible,0.01796668737531745
conclude,0.01796668737531745
bayes,0.01796668737531745
differences,0.01796668737531745
hypotheses,0.01796668737531745
denotes,0.01796668737531745
curves,0.01796668737531745
statistics,0.01699174424751606
cross,0.01699174424751606
necessary,0.01699174424751606
targeted,0.01699174424751606
fixed,0.01699174424751606
sampling,0.01699174424751606
estimation,0.01699174424751606
corresponding,0.01699174424751606
board,0.01699174424751606
simons,0.01699174424751606
cost,0.01699174424751606
cells,0.016746781819180184
count,0.016746781819180184
grade,0.016746781819180184
days,0.016746781819180184
proportion,0.016069172421135043
refer,0.016069172421135043
minimal,0.016069172421135043
right,0.016069172421135043
parameters,0.016069172421135043
80,0.016069172421135043
superiority,0.015503777057325885
journal,0.015503777057325885
ratios,0.015503777057325885
natural,0.015503777057325885
pcra,0.015503777057325885
bias,0.015503777057325885
checked,0.015503777057325885
planning,0.015503777057325885
confounders,0.015503777057325885
corresponds,0.015503777057325885
thickness,0.015503777057325885
designs,0.015503777057325885
discontinued,0.015040624911189585
analyzed,0.015040624911189585
grfs,0.015040624911189585
estimate,0.015040624911189585
106,0.015040624911189585
fully,0.015040624911189585
respectively,0.015040624911189585
values,0.015040624911189585
severity,0.014354384416440158
levels,0.014354384416440158
retinal,0.014354384416440158
specific,0.014354384416440158
stem,0.014354384416440158
early,0.014354384416440158
increase,0.014354384416440158
additional,0.014354384416440158
kilograms,0.014354384416440158
optimal,0.014354384416440158
duration,0.014354384416440158
85,0.013593395398012848
tested,0.013593395398012848
questions,0.013593395398012848
equal,0.013593395398012848
proportions,0.013593395398012848
half,0.013593395398012848
prevalence,0.013593395398012848
experienced,0.013593395398012848
compliance,0.013593395398012848
missing,0.013593395398012848
extension,0.013593395398012848
saes,0.013593395398012848
sequentially,0.013593395398012848
pga,0.013593395398012848
conjugate,0.013593395398012848
depending,0.013593395398012848
deaths,0.013593395398012848
posteriori,0.013475015531488086
causal,0.013475015531488086
window,0.013475015531488086
1999,0.013475015531488086
resulting,0.013475015531488086
computing,0.013475015531488086
berry,0.013475015531488086
qualitative,0.013475015531488086
assumption,0.013475015531488086
h1,0.013475015531488086
terminated,0.013475015531488086
intercept,0.013475015531488086
accumulated,0.013475015531488086
81,0.013475015531488086
low,0.013390977017612538
family,0.013390977017612538
cause,0.013390977017612538
selection,0.013390977017612538
consent,0.013390977017612538
hospitalization,0.013390977017612538
hospital,0.013390977017612538
ensure,0.013390977017612538
costs,0.013390977017612538
testing,0.013390977017612538
toxicities,0.012032499928951668
optical,0.012032499928951668
cohorts,0.012032499928951668
platelets,0.012032499928951668
class,0.012032499928951668
final,0.012032499928951668
functions,0.012032499928951668
directly,0.012032499928951668
relative,0.012032499928951668
judgment,0.012032499928951668
known,0.012032499928951668
weight,0.012032499928951668
lower,0.012032499928951668
coherence,0.012032499928951668
70,0.011961987013700133
date,0.011961987013700133
adapted,0.011961987013700133
doses,0.011961987013700133
lesions,0.011961987013700133
health,0.011961987013700133
eye,0.011961987013700133
assessment,0.011961987013700133
severe,0.011961987013700133
life,0.011961987013700133
hematopoietic,0.011961987013700133
decision,0.011961987013700133
high,0.011961987013700133
preferred,0.011627832792994413
vaccine,0.011627832792994413
2018,0.011627832792994413
regardless,0.011627832792994413
validity,0.011627832792994413
dropping,0.011627832792994413
2006,0.011627832792994413
close,0.011627832792994413
precluding,0.011627832792994413
variables,0.011627832792994413
settings,0.011627832792994413
conclusions,0.011627832792994413
censoring,0.011627832792994413
sizes,0.011627832792994413
benefits,0.011627832792994413
sum,0.011627832792994413
truncation,0.011627832792994413
controlling,0.011627832792994413
incorporating,0.011627832792994413
major,0.01071278161409003
transfusion,0.01071278161409003
perform,0.01071278161409003
exposed,0.01071278161409003
pr,0.01071278161409003
central,0.01071278161409003
status,0.01071278161409003
report,0.01071278161409003
different,0.01071278161409003
regulatory,0.01071278161409003
mesenchymal,0.01071278161409003
allow,0.01071278161409003
tocilizumab,0.01071278161409003
adalimumab,0.01071278161409003
start,0.01071278161409003
decrease,0.01071278161409003
stromal,0.01071278161409003
2017,0.010195046548509636
description,0.010195046548509636
actg,0.010195046548509636
length,0.010195046548509636
enroll,0.010195046548509636
minimum,0.010195046548509636
numbers,0.010195046548509636
diagnosis,0.010195046548509636
affect,0.010195046548509636
basis,0.010195046548509636
approximately,0.010195046548509636
stratified,0.010195046548509636
recruited,0.010195046548509636
rule,0.010195046548509636
graaph,0.010195046548509636
beneficial,0.010195046548509636
2011,0.010195046548509636
period,0.009569589610960105
available,0.009569589610960105
weeks,0.009569589610960105
chronic,0.009569589610960105
multiple,0.009569589610960105
possible,0.009024374946713749
bmt,0.009024374946713749
comparing,0.009024374946713749
performans,0.009024374946713749
tomography,0.009024374946713749
absolute,0.009024374946713749
provide,0.009024374946713749
ion,0.009024374946713749
65,0.009024374946713749
21,0.009024374946713749
adaptive,0.009024374946713749
occurring,0.009024374946713749
target,0.009024374946713749
effective,0.009024374946713749
ecog,0.009024374946713749
act,0.009024374946713749
receive,0.009024374946713749
reconstitution,0.009024374946713749
method,0.009024374946713749
objective,0.009024374946713749
hydrogen,0.009024374946713749
aims,0.009024374946713749
stay,0.009024374946713749
ref,0.009024374946713749
common,0.009024374946713749
chained,0.008983343687658725
fishers,0.008983343687658725
retrospectively,0.008983343687658725
waiting,0.008983343687658725
begin,0.008983343687658725
assumptions,0.008983343687658725
10000,0.008983343687658725
yes,0.008983343687658725
comparisons,0.008983343687658725
suited,0.008983343687658725
request,0.008983343687658725
presents,0.008983343687658725
prob,0.008983343687658725
requested,0.008983343687658725
indicate,0.008983343687658725
imbalances,0.008983343687658725
successively,0.008983343687658725
biased,0.008983343687658725
demonstration,0.008983343687658725
remaining,0.008983343687658725
weighting,0.008983343687658725
zhou,0.008983343687658725
fictive,0.008983343687658725
margin,0.008983343687658725
loghr,0.008983343687658725
sharma,0.008983343687658725
petersen,0.008983343687658725
dsi,0.008983343687658725
rejected,0.008983343687658725
9th,0.008983343687658725
ivanova,0.008983343687658725
decide,0.008983343687658725
inefficacious,0.008983343687658725
invest,0.008983343687658725
descriptive,0.008983343687658725
distributed,0.008983343687658725
detect,0.008983343687658725
mid,0.008983343687658725
inflation,0.008983343687658725
additionally,0.008983343687658725
accrued,0.008983343687658725
nk,0.008034586210567522
effects,0.008034586210567522
mortality,0.008034586210567522
outcomes,0.008034586210567522
function,0.008034586210567522
single,0.008034586210567522
withdrawal,0.008034586210567522
48,0.008034586210567522
exposure,0.008034586210567522
measure,0.008034586210567522
2012,0.008034586210567522
visual,0.008034586210567522
2016,0.008034586210567522
prednisone,0.008034586210567522
laboratory,0.008034586210567522
neutrophils,0.008034586210567522
https,0.008034586210567522
uninjected,0.008034586210567522
cycles,0.008034586210567522
organ,0.008034586210567522
aiec,0.008034586210567522
term,0.008034586210567522
true,0.007751888528662943
randomisation,0.007751888528662943
particularly,0.007751888528662943
uniform,0.007751888528662943
external,0.007751888528662943
bn,0.007751888528662943
spending,0.007751888528662943
percent,0.007751888528662943
med,0.007751888528662943
finite,0.007751888528662943
york,0.007751888528662943
variable,0.007751888528662943
worthy,0.007751888528662943
wang,0.007751888528662943
detecting,0.007751888528662943
lee,0.007751888528662943
density,0.007751888528662943
intention,0.007751888528662943
multicenter,0.007751888528662943
introducing,0.007751888528662943
inefficacy,0.007751888528662943
investment,0.007751888528662943
interpreted,0.007751888528662943
address,0.007751888528662943
94,0.007751888528662943
equation,0.007751888528662943
critical,0.007751888528662943
ctae,0.007751888528662943
secondly,0.007751888528662943
clin,0.007751888528662943
2010,0.007751888528662943
37,0.007751888528662943
financial,0.007751888528662943
finally,0.007751888528662943
poorly,0.007751888528662943
populations,0.007751888528662943
subgroup,0.007751888528662943
analyzing,0.007751888528662943
greatly,0.007751888528662943
grading,0.007751888528662943
handling,0.007751888528662943
courses,0.007751888528662943
inactivity,0.007751888528662943
anticipated,0.007751888528662943
hope,0.007751888528662943
primarily,0.007751888528662943
consultations,0.007751888528662943
confounding,0.007751888528662943
termination,0.007751888528662943
therapy,0.007177192208220079
milligrams,0.007177192208220079
amplification,0.007177192208220079
concentration,0.007177192208220079
medical,0.007177192208220079
50,0.007177192208220079
capmatinib,0.007177192208220079
behcets,0.007177192208220079
care,0.007177192208220079
40,0.007177192208220079
year,0.007177192208220079
met,0.007177192208220079
rates,0.007177192208220079
independent,0.007177192208220079
steroids,0.007177192208220079
reported,0.007177192208220079
outcome,0.007177192208220079
order,0.007177192208220079
anti,0.007177192208220079
conclusion,0.006796697699006424
2015,0.006796697699006424
excluded,0.006796697699006424
ferritin,0.006796697699006424
cmv,0.006796697699006424
responding,0.006796697699006424
gammaglobulin,0.006796697699006424
c30,0.006796697699006424
comparative,0.006796697699006424
chose,0.006796697699006424
alternative,0.006796697699006424
subcutaneously,0.006796697699006424
replaced,0.006796697699006424
decided,0.006796697699006424
outside,0.006796697699006424
reporting,0.006796697699006424
correlation,0.006796697699006424
controls,0.006796697699006424
requirements,0.006796697699006424
appears,0.006796697699006424
immunization,0.006796697699006424
subgroups,0.006796697699006424
independently,0.006796697699006424
enrollment,0.006796697699006424
eortc,0.006796697699006424
admission,0.006796697699006424
tolerability,0.006796697699006424
purpose,0.006796697699006424
questionnaire,0.006796697699006424
molecular,0.006796697699006424
eradication,0.006796697699006424
large,0.006796697699006424
updated,0.006796697699006424
died,0.006796697699006424
involve,0.006796697699006424
v3,0.006796697699006424
details,0.006796697699006424
microns,0.006796697699006424
limit,0.006016249964475834
underlying,0.006016249964475834
300,0.006016249964475834
allowing,0.006016249964475834
age,0.006016249964475834
terminology,0.006016249964475834
account,0.006016249964475834
uncontrolled,0.006016249964475834
allows,0.006016249964475834
acuity,0.006016249964475834
note,0.006016249964475834
national,0.006016249964475834
2003,0.006016249964475834
erythrocyte,0.006016249964475834
protein,0.006016249964475834
22,0.006016249964475834
practice,0.006016249964475834
positive,0.006016249964475834
reactive,0.006016249964475834
developed,0.006016249964475834
ebv,0.006016249964475834
2008,0.006016249964475834
version,0.006016249964475834
donors,0.006016249964475834
chosen,0.006016249964475834
corrected,0.006016249964475834
consecutive,0.006016249964475834
respond,0.006016249964475834
shown,0.006016249964475834
occurs,0.006016249964475834
association,0.006016249964475834
beginning,0.006016249964475834
interaction,0.005356390807045015
standardization,0.005356390807045015
injected,0.005356390807045015
bd,0.005356390807045015
starting,0.005356390807045015
belimumab,0.005356390807045015
partial,0.005356390807045015
sparing,0.005356390807045015
haze,0.005356390807045015
committee,0.005356390807045015
higher,0.005356390807045015
place,0.005356390807045015
33,0.005356390807045015
17,0.005356390807045015
usual,0.005356390807045015
11,0.005356390807045015
transfusions,0.005356390807045015
terms,0.005356390807045015
tolerance,0.005356390807045015
subject,0.005356390807045015
louis,0.005356390807045015
loss,0.005356390807045015
18,0.005356390807045015
line,0.005356390807045015
nomenclature,0.005356390807045015
ks,0.005356390807045015
appropriate,0.005356390807045015
plan,0.005356390807045015
reduce,0.005356390807045015
follows,0.005356390807045015
presence,0.005356390807045015
present,0.005356390807045015
visit,0.005356390807045015
concerning,0.005356390807045015
engraftment,0.005356390807045015
infusion,0.004784794805480053
activity,0.004784794805480053
infections,0.004784794805480053
uveitis,0.004784794805480053
vitreous,0.004784794805480053
et,0.004784794805480053
vasculitis,0.004784794805480053
donor,0.004784794805480053
failure,0.004784794805480053
macular,0.004784794805480053
evidence,0.004784794805480053
refractory,0.004784794805480053
pre,0.004784794805480053
placebo,0.004784794805480053
chimerism,0.004784794805480053
peripheral,0.004784794805480053
complications,0.004784794805480053
ongoing,0.004784794805480053
red,0.004784794805480053
resolution,0.004784794805480053
corticosteroid,0.004784794805480053
immune,0.004784794805480053
second,0.004784794805480053
intravenous,0.004784794805480053
associated,0.004784794805480053
step,0.004784794805480053
systemic,0.004784794805480053
aesi,0.004491671843829362
admissions,0.004491671843829362
inverse,0.004491671843829362
nilotinib,0.004491671843829362
applying,0.004491671843829362
jm,0.004491671843829362
ja,0.004491671843829362
leave,0.004491671843829362
amendment,0.004491671843829362
subsets,0.004491671843829362
january,0.004491671843829362
suspended,0.004491671843829362
survive,0.004491671843829362
annals,0.004491671843829362
na,0.004491671843829362
multiplicity,0.004491671843829362
monitor,0.004491671843829362
modify,0.004491671843829362
modelling,0.004491671843829362
sylvie,0.004491671843829362
linearity,0.004491671843829362
modeling,0.004491671843829362
suspicion,0.004491671843829362
tools,0.004491671843829362
146,0.004491671843829362
ya,0.004491671843829362
matthieu,0.004491671843829362
111,0.004491671843829362
06,0.004491671843829362
62,0.004491671843829362
add,0.004491671843829362
chevret,0.004491671843829362
checking,0.004491671843829362
impacts,0.004491671843829362
res,0.004491671843829362
pooled,0.004491671843829362
confirmatory,0.004491671843829362
residuals,0.004491671843829362
computation,0.004491671843829362
roughly,0.004491671843829362
retained,0.004491671843829362
scales,0.004491671843829362
chi,0.004491671843829362
semi,0.004491671843829362
coded,0.004491671843829362
clinicians,0.004491671843829362
handle,0.004491671843829362
collects,0.004491671843829362
htm,0.004491671843829362
centered,0.004491671843829362
simulations,0.004491671843829362
obtention,0.004491671843829362
biostatistics,0.004491671843829362
balanced,0.004491671843829362
incomplete,0.004491671843829362
spiegelhalter,0.004491671843829362
spline,0.004491671843829362
square,0.004491671843829362
chance,0.004491671843829362
smoothing,0.004491671843829362
soon,0.004491671843829362
frequencies,0.004491671843829362
rely,0.004491671843829362
goes,0.004491671843829362
representing,0.004491671843829362
going,0.004491671843829362
fitting,0.004491671843829362
exceed,0.004491671843829362
economic,0.004491671843829362
price,0.004491671843829362
der,0.004491671843829362
formulation,0.004491671843829362
doi,0.004491671843829362
represented,0.004491671843829362
csi,0.004491671843829362
ctc_50,0.004491671843829362
ctep,0.004491671843829362
densities,0.004491671843829362
predictors,0.004491671843829362
defining,0.004491671843829362
frequentist,0.004491671843829362
filled,0.004491671843829362
enrolling,0.004491671843829362
probabilities,0.004491671843829362
electronic_applications,0.004491671843829362
entered,0.004491671843829362
empirical,0.004491671843829362
reach,0.004491671843829362
quickly,0.004491671843829362
enhance,0.004491671843829362
fall,0.004491671843829362
purposes,0.004491671843829362
protocoldevelopment,0.004491671843829362
quantity,0.004491671843829362
making,0.004491671843829362
variance,0.004491671843829362
wilcoxons,0.004491671843829362
withdrawals,0.004491671843829362
03,0.0038759442643314713
way,0.0038759442643314713
web,0.0038759442643314713
magic,0.0038759442643314713
lymphedema,0.0038759442643314713
tyndall,0.0038759442643314713
marginal,0.0038759442643314713
market,0.0038759442643314713
matching,0.0038759442643314713
meaning,0.0038759442643314713
light,0.0038759442643314713
ex,0.0038759442643314713
projected,0.0038759442643314713
effectively,0.0038759442643314713
eventually,0.0038759442643314713
transmitted,0.0038759442643314713
92,0.0038759442643314713
donnees,0.0038759442643314713
department,0.0038759442643314713
rare,0.0038759442643314713
reached,0.0038759442643314713
66,0.0038759442643314713
randomly,0.0038759442643314713
activities,0.0038759442643314713
fewer,0.0038759442643314713
extracted,0.0038759442643314713
questionaire,0.0038759442643314713
2021,0.0038759442643314713
published,0.0038759442643314713
units,0.0038759442643314713
34,0.0038759442643314713
43,0.0038759442643314713
1994,0.0038759442643314713
shows,0.0038759442643314713
immunosuppressives,0.0038759442643314713
162,0.0038759442643314713
escalation,0.0038759442643314713
reappearance,0.0038759442643314713
toxic,0.0038759442643314713
tomographic,0.0038759442643314713
accordingly,0.0038759442643314713
accounting,0.0038759442643314713
accrual,0.0038759442643314713
reactivations,0.0038759442643314713
reasonable,0.0038759442643314713
anakinra,0.0038759442643314713
policy,0.0038759442643314713
crossed,0.0038759442643314713
kawasaki,0.0038759442643314713
laws,0.0038759442643314713
lariboisiere,0.0038759442643314713
allowed,0.0038759442643314713
aes,0.0038759442643314713
actual,0.0038759442643314713
titers,0.0038759442643314713
decisions,0.0038759442643314713
recoveries,0.0038759442643314713
precision,0.0038759442643314713
fleming,0.0038759442643314713
studied,0.0038759442643314713
globally,0.0038759442643314713
subsequent,0.0038759442643314713
larger,0.0038759442643314713
surveillance,0.0038759442643314713
snellen,0.0038759442643314713
simon,0.0038759442643314713
2019,0.0038759442643314713
esr,0.0038759442643314713
conversely,0.0038759442643314713
vfq,0.0038759442643314713
van,0.0038759442643314713
2020,0.0038759442643314713
screened,0.0038759442643314713
implies,0.0038759442643314713
initially,0.0038759442643314713
stages,0.0038759442643314713
standards,0.0038759442643314713
functioning,0.0038759442643314713
st,0.0038759442643314713
incidences,0.0038759442643314713
occur,0.0038759442643314713
neutrophiles,0.0038759442643314713
obrien,0.0038759442643314713
result,0.0038759442643314713
scored,0.0038759442643314713
appeared,0.0038759442643314713
individual,0.0038759442643314713
application,0.0038759442643314713
stock,0.0038759442643314713
assessing,0.0038759442643314713
world,0.003398348849503212
effectiveness,0.003398348849503212
electronic,0.003398348849503212
prospectively,0.003398348849503212
ensuring,0.003398348849503212
zero,0.003398348849503212
120,0.003398348849503212
mainly,0.003398348849503212
make,0.003398348849503212
2005,0.003398348849503212
allocated,0.003398348849503212
prednisolone,0.003398348849503212
targets,0.003398348849503212
survey,0.003398348849503212
logmar,0.003398348849503212
analyze,0.003398348849503212
later,0.003398348849503212
54,0.003398348849503212
earlier,0.003398348849503212
drugs,0.003398348849503212
questionnaires,0.003398348849503212
preexisting,0.003398348849503212
explored,0.003398348849503212
features,0.003398348849503212
easily,0.003398348849503212
access,0.003398348849503212
acceptable,0.003398348849503212
action,0.003398348849503212
reaches,0.003398348849503212
leakage,0.003398348849503212
discharge,0.003398348849503212
records,0.003398348849503212
reactants,0.003398348849503212
gov,0.003398348849503212
platform,0.003398348849503212
ctc,0.003398348849503212
angiography,0.003398348849503212
investigating,0.003398348849503212
independence,0.003398348849503212
observational,0.003398348849503212
growth,0.003398348849503212
schedule,0.003398348849503212
scheduled,0.003398348849503212
assigned,0.003398348849503212
applied,0.003398348849503212
newly,0.003398348849503212
stated,0.003398348849503212
average,0.003398348849503212
nb,0.003398348849503212
spontaneous,0.003398348849503212
chelation,0.003398348849503212
paraclinical,0.003398348849503212
outpatient,0.003398348849503212
organs,0.003398348849503212
optimized,0.003398348849503212
sedimentation,0.003398348849503212
clinic,0.003398348849503212
special,0.003398348849503212
similar,0.003398348849503212
qlq,0.003398348849503212
validate,0.003398348849503212
40mg,0.003398348849503212
v4,0.003398348849503212
400,0.003398348849503212
epidemiology,0.003398348849503212
49,0.003008124982237917
29,0.003008124982237917
provided,0.003008124982237917
vital,0.003008124982237917
35,0.003008124982237917
sibling,0.003008124982237917
charge,0.003008124982237917
usually,0.003008124982237917
impact,0.003008124982237917
pathology,0.003008124982237917
hopital,0.003008124982237917
implemented,0.003008124982237917
institute,0.003008124982237917
indexed,0.003008124982237917
collect,0.003008124982237917
gamma,0.003008124982237917
binding,0.003008124982237917
immediate,0.003008124982237917
search,0.003008124982237917
overlap,0.003008124982237917
recommendation,0.003008124982237917
diseases,0.003008124982237917
tolerated,0.003008124982237917
evaluate,0.003008124982237917
fact,0.003008124982237917
examination,0.003008124982237917
endoscopic,0.003008124982237917
80mg,0.003008124982237917
measurement,0.003008124982237917
meet,0.003008124982237917
lymphocyte,0.003008124982237917
participants,0.003008124982237917
continue,0.003008124982237917
flare,0.003008124982237917
choice,0.003008124982237917
combined,0.003008124982237917
american,0.003008124982237917
left,0.003008124982237917
saint,0.003008124982237917
complementary,0.003008124982237917
global,0.003008124982237917
repeated,0.003008124982237917
modification,0.003008124982237917
replacement,0.003008124982237917
define,0.003008124982237917
adequate,0.003008124982237917
detailed,0.003008124982237917
relapses,0.003008124982237917
meeting,0.003008124982237917
law,0.003008124982237917
taking,0.003008124982237917
graall,0.003008124982237917
decreased,0.003008124982237917
recent,0.003008124982237917
potentially,0.003008124982237917
addition,0.003008124982237917
formula,0.003008124982237917
transplanted,0.003008124982237917
proposed,0.003008124982237917
protection,0.003008124982237917
worsening,0.003008124982237917
13,0.003008124982237917
change,0.0026781954035225075
2013,0.0026781954035225075
visits,0.0026781954035225075
limited,0.0026781954035225075
chamber,0.0026781954035225075
significant,0.0026781954035225075
manifestations,0.0026781954035225075
medications,0.0026781954035225075
medium,0.0026781954035225075
principal,0.0026781954035225075
centre,0.0026781954035225075
assess,0.0026781954035225075
isatuximab,0.0026781954035225075
good,0.0026781954035225075
obtain,0.0026781954035225075
hospitalizations,0.0026781954035225075
collected,0.0026781954035225075
specified,0.0026781954035225075
classification,0.0026781954035225075
onset,0.0026781954035225075
camostat,0.0026781954035225075
cancer,0.0026781954035225075
eligibility,0.0026781954035225075
recommended,0.0026781954035225075
concomitant,0.0026781954035225075
residual,0.0026781954035225075
des,0.0026781954035225075
able,0.0026781954035225075
reference,0.0026781954035225075
receiving,0.0026781954035225075
mixed,0.0026781954035225075
long,0.0026781954035225075
late,0.0026781954035225075
syndromes,0.0026781954035225075
taken,0.0026781954035225075
reduction,0.0026781954035225075
flow,0.0026781954035225075
antibody,0.0026781954035225075
45,0.0026781954035225075
matched,0.0026781954035225075
composite,0.0026781954035225075
cov2,0.0026781954035225075
identical,0.0026781954035225075
paris,0.0026781954035225075
ileal,0.0026781954035225075
imaging,0.0026781954035225075
biopsies,0.0026781954035225075
infectious,0.0026781954035225075
support,0.0026781954035225075
platelet,0.0026781954035225075
appendix,0.0026781954035225075
surgery,0.0026781954035225075
unit,0.0023923974027400263
vessel,0.0023923974027400263
19,0.0023923974027400263
unrelated,0.0023923974027400263
modified,0.0023923974027400263
cryoglobulinemia,0.0023923974027400263
sars,0.0023923974027400263
involvement,0.0023923974027400263
steroid,0.0023923974027400263
conditioning,0.0023923974027400263
poor,0.0023923974027400263
infection,0.0023923974027400263
cardiac,0.0023923974027400263
injection,0.0023923974027400263
ocular,0.0023923974027400263
increased,0.0023923974027400263
collection,0.0023923974027400263
haplo,0.0023923974027400263
benefit,0.0023923974027400263
signs,0.0023923974027400263
current,0.0023923974027400263
daily,0.0023923974027400263
plasma,0.0023923974027400263
syndrome,0.0023923974027400263
followed,0.0023923974027400263
anterior,0.0023923974027400263
edema,0.0023923974027400263
prca,0.0023923974027400263
tnf,0.0023923974027400263
active,0.0023923974027400263
previously,0.0023923974027400263
management,0.0023923974027400263
procedure,0.0023923974027400263
evolution,0.0023923974027400263
